TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $122.70.

Several brokerages have recently issued reports on TMDX. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a research note on Tuesday, December 3rd. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Piper Sandler decreased their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Finally, TD Cowen cut their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. This represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,459 shares of company stock valued at $1,802,244 in the last 90 days. 7.00% of the stock is currently owned by company insiders.

Institutional Trading of TransMedics Group

A number of hedge funds and other institutional investors have recently modified their holdings of TMDX. Principal Financial Group Inc. grew its stake in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after purchasing an additional 146,115 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of TransMedics Group in the third quarter valued at $149,000. Sanctuary Advisors LLC increased its holdings in TransMedics Group by 63.4% during the third quarter. Sanctuary Advisors LLC now owns 4,041 shares of the company’s stock worth $634,000 after buying an additional 1,568 shares during the last quarter. Morse Asset Management Inc bought a new stake in TransMedics Group during the third quarter worth $823,000. Finally, Virtu Financial LLC acquired a new stake in TransMedics Group in the third quarter valued at $436,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $59.28 on Tuesday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm has a market cap of $1.99 billion, a PE ratio of 63.06 and a beta of 2.06. TransMedics Group has a twelve month low of $58.27 and a twelve month high of $177.37. The business has a fifty day moving average of $80.40 and a 200-day moving average of $125.46.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business’s revenue for the quarter was up 63.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.12) EPS. On average, equities research analysts predict that TransMedics Group will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.